Surmodics, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported revenue was USD 132.58 million compared to USD 99.95 million a year ago. Net loss was USD 1.54 million compared to USD 27.27 million a year ago.

Basic loss per share from continuing operations was USD 0.11 compared to USD 1.96 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 1.96 a year ago.